Diagnosis, staging, and surveillance of cervical carcinoma

H Kaur, PM Silverman, RB Iyer… - American Journal of …, 2003 - Am Roentgen Ray Soc
Cervical cancer is the third most common gynecologic malignancy. In the United States, it is
anticipated that 13,000 new cases of cervical cancer will be diagnosed in 2002, and 4100 …

[HTML][HTML] New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas

BT Mossman, A Shukla, NH Heintz… - The American journal of …, 2013 - Elsevier
Malignant mesothelioma (MM) is a relatively rare but devastating tumor that is increasing
worldwide. Yet, because of difficulties in early diagnosis and resistance to conventional …

Incidence and survival rates for female malignant germ cell tumors

HO Smith, M Berwick, CF Verschraegen… - Obstetrics & …, 2006 - journals.lww.com
OBJECTIVE: To evaluate 30-year, population-based trends in incidence and survival rates
for malignant germ cell tumors originating within the female genital tract. METHODS …

GPR30 predicts poor survival for ovarian cancer

HO Smith, H Arias-Pulido, DY Kuo, T Howard… - Gynecologic …, 2009 - Elsevier
OBJECTIVES: GPR30 is a 7-transmembrane G protein-coupled estrogen receptor that
functions alongside traditional estrogen receptors to regulate cellular responses to estrogen …

Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic …

S Vadhan-Raj, CF Verschraegen… - Annals of internal …, 2000 - acpjournals.org
Background: Thrombocytopenia is a significant problem in the treatment of cancer.
Objective: To assess the clinical safety of therapy with recombinant human thrombopoietin …

Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20 (s)-camptothecin in patients with advanced pulmonary malignancies

CF Verschraegen, BE Gilbert, E Loyer, A Huaringa… - Clinical Cancer …, 2004 - AACR
Purpose: The purpose is to evaluate the feasibility and safety of aerosol administration of the
topoisomerase I inhibitor, 9-nitrocamptothecin, in a liposome formulation, and to recommend …

Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies

JJ Luke, SA Piha-Paul, T Medina… - Clinical Cancer …, 2023 - AACR
Purpose: SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle 1917
(EcN) engineered to produce cyclic dinucleotides under hypoxia, leading to STimulator of …

Vulvar melanoma at the MD Anderson Cancer Center: 25 years later

CF Verschraegen, M Benjapibal… - International Journal of …, 2001 - ijgc.bmj.com
The purpose of this study was to review the clinical course of patients diagnosed with vulvar
melanoma. Charts of patients diagnosed between 1970 and 1997 were reviewed for …

[PDF][PDF] Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

CF Verschraegen, T Levy, AP Kudelka… - Journal of clinical …, 1997 - Citeseer
Purpose: A phase II study was performed to evaluate the antitumor activity and toxicity of
irinotecan (CPT-1 1), a water-soluble derivative of camptothecin, in patients with prior …

[PDF][PDF] Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial

GR Simon, CF Verschraegen, PA Jänne… - Journal of Clinical …, 2008 - researchgate.net
Purpose Pemetrexed in combination with cisplatin is approved for the treatment of pleural
mesothelioma and is active in malignant peritoneal mesothelioma (MPeM). Pemetrexed and …